Targeting Strategies for the Combination Treatment of Cancer Using Drug Delivery Systems
Open Access
- 14 October 2017
- journal article
- review article
- Published by MDPI AG in Pharmaceutics
- Vol. 9 (4), 46
- https://doi.org/10.3390/pharmaceutics9040046
Abstract
Cancer cells have characteristics of acquired and intrinsic resistances to chemotherapy treatment—due to the hostile tumor microenvironment—that create a significant challenge for effective therapeutic regimens. Multidrug resistance, collateral toxicity to normal cells, and detrimental systemic side effects present significant obstacles, necessitating alternative and safer treatment strategies. Traditional administration of chemotherapeutics has demonstrated minimal success due to the non-specificity of action, uptake and rapid clearance by the immune system, and subsequent metabolic alteration and poor tumor penetration. Nanomedicine can provide a more effective approach to targeting cancer by focusing on the vascular, tissue, and cellular characteristics that are unique to solid tumors. Targeted methods of treatment using nanoparticles can decrease the likelihood of resistant clonal populations of cancerous cells. Dual encapsulation of chemotherapeutic drug allows simultaneous targeting of more than one characteristic of the tumor. Several first-generation, non-targeted nanomedicines have received clinical approval starting with Doxil® in 1995. However, more than two decades later, second-generation or targeted nanomedicines have yet to be approved for treatment despite promising results in pre-clinical studies. This review highlights recent studies using targeted nanoparticles for cancer treatment focusing on approaches that target either the tumor vasculature (referred to as ‘vascular targeting’), the tumor microenvironment (‘tissue targeting’) or the individual cancer cells (‘cellular targeting’). Recent studies combining these different targeting methods are also discussed in this review. Finally, this review summarizes some of the reasons for the lack of clinical success in the field of targeted nanomedicines.Funding Information
- National Institute of Health (R00CA153948, K99CA153948)
This publication has 153 references indexed in Scilit:
- Tumor-Targeting and Microenvironment-Responsive Smart Nanoparticles for Combination Therapy of Antiangiogenesis and ApoptosisACS Nano, 2013
- Transferrin-functionalized nanoparticles lose their targeting capabilities when a biomolecule corona adsorbs on the surfaceNature Nanotechnology, 2013
- Mechanisms and insights into drug resistance in cancerFrontiers in Pharmacology, 2013
- Precise glioma targeting of and penetration by aptamer and peptide dual-functioned nanoparticlesBiomaterials, 2012
- Biocompatibility of Fe3O4/DNR magnetic nanoparticles in the treatment of hematologic malignanciesInternational Journal of Nanomedicine, 2010
- A Reexamination of Active and Passive Tumor Targeting by Using Rod-Shaped Gold Nanocrystals and Covalently Conjugated Peptide LigandsACS Nano, 2010
- Selective and effective killing of angiogenic vascular endothelial cells and cancer cells by targeting tissue factor using a factor VII-targeted photodynamic therapy for breast cancerBreast Cancer Research and Treatment, 2010
- Targeting tissue factor on tumour cells and angiogenic vascular endothelial cells by factor VII-targeted verteporfin photodynamic therapy for breast cancer in vitro and in vivoin miceBMC Cancer, 2010
- Labeling TiO2 Nanoparticles with Dyes for Optical Fluorescence Microscopy and Determination of TiO2–DNA Nanoconjugate StabilitySmall, 2009
- Mechanisms of Disease: oncogene addiction—a rationale for molecular targeting in cancer therapyNature Clinical Practice Oncology, 2006